Ulocuplumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | C-X-C chemokine receptor type 4 |
Clinical data | |
Other names | MDX-1338 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6486H9960N1720O2046S46 |
Molar mass | 146243.78 g·mol−1 |
Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]
This drug was developed by Bristol-Myers Squibb.
References[]
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs